FONT-SIZE Plus   Neg

Boehringer Ingelheim, Eli Lilly Submit NDA For Empagliflozin - Quick Facts

Boehringer Ingelheim and Eli Lilly and Company (LLY) announced that a New Drug Application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin was recently submitted to the FDA for the treatment of type 2 diabetes mellitus in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a sign that other retailers may be re-thinking their Thanksgiving hours, Staples will be closed for the day. Like Wal-Mart and others, Staples was open on Thanksgiving Day for the past two years. European Court of Justice in Luxembourg has canceled the international agreement between European Union and United States to handover digital information, such as web search histories and social media updates. The ruling will be a blow to tech giants Google, Microsoft, Facebook, Amazon, etc. Volkswagen Australia Wednesday confirmed that more than 91 thousand vehicles sold in Australia were fitted with emission cheating software. Volkswagen brand alone comes to 77,000 cars and 14,000 cars are Audis.
comments powered by Disqus
Follow RTT